An­a­lysts hound Bio­gen with ques­tions over Aduhelm's $56K price point as news of Alzheimer's OK rip­ples through glob­al mar­kets

It’s been near­ly 24 hours since the FDA hand­ed down its con­tro­ver­sial de­ci­sion to ap­prove Bio­gen’s Aduhelm drug for Alzheimer’s dis­ease, and re­ac­tions from around the in­dus­try are pour­ing in as an­a­lysts try to size up the ram­i­fi­ca­tions of Mon­day’s news.

Bio­gen host­ed an in­vestor call Tues­day morn­ing, pro­vid­ing a fo­rum for a num­ber of top­ics that have been top of mind. The call came as the news of Aduhelm’s ap­proval in the US rip­pled through glob­al mar­kets, while $BI­IB stock soared to around $380 apiece (up from $286 on Fri­day), as Bio­gen’s part­ners at Ei­sai seek new ap­provals in Asia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER